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Abstract: Osteoporosis is a complex multifactorial disorder of the skeleton. Genetic factors are
important in determining peak bone mass and structure, as well as the predisposition to bone
deterioration and fragility fractures. Nonetheless, genetic factors alone are not sufficient to explain
osteoporosis development and fragility fracture occurrence. Indeed, epigenetic factors, representing
a link between individual genetic aspects and environmental influences, are also strongly suspected
to be involved in bone biology and osteoporosis. Recently, alterations in epigenetic mechanisms
and their activity have been associated with aging. Also, bone metabolism has been demonstrated
to be under the control of epigenetic mechanisms. Runt-related transcription factor 2 (RUNX2),
the master transcription factor of osteoblast differentiation, has been shown to be regulated by histone
deacetylases and microRNAs (miRNAs). Some miRNAs were also proven to have key roles in the
regulation of Wnt signalling in osteoblastogenesis, and to be important for the positive or negative
regulation of both osteoblast and osteoclast differentiation. Exogenous and environmental stimuli,
influencing the functionality of epigenetic mechanisms involved in the regulation of bone metabolism,
may contribute to the development of osteoporosis and other bone disorders, in synergy with genetic
determinants. The progressive understanding of roles of epigenetic mechanisms in normal bone
metabolism and in multifactorial bone disorders will be very helpful for a better comprehension of
disease pathogenesis and translation of this information into clinical practice. A deep understanding
of these mechanisms could help in the future tailoring of proper individual treatments, according to
precision medicine’s principles.
Keywords: gene expression; histone modifications; DNA methylation; microRNAs; precision
medicine; fragility fracture
1. Introduction
Osteoporosis, a metabolic skeletal disorder, is a consequence of disrupted normal bone turnover,
resulting in reduction of bone mass and mineralization and severe alteration of bone micro-architecture.
As a consequence of these structural modifications, osteoporotic bone tissue presents reduced strength
that is associated with a high risk of fragility fractures. It is a complex multifactorial disorder
resulting from an interaction between genetic and environmental factors, dietary habits, and lifestyle.
The focal point of osteoporosis is the deregulation of bone turnover. Normally, in adult skeleton
bone remodelling is maintained in a tight balance by highly regulated differentiation, activity, and
apoptosis of bone-forming osteoblasts and bone-resorbing osteoclasts. Differentiation of osteoblasts
and osteoclasts is finely tuned by profound changes in the expression of numerous regulatory genes.
Changes in the expression of these genes could result in altered bone homeostasis and the manifestation
of osteoporosis. Family and twin studies confirmed the importance of heritability and genetic profiles in
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the determination of bone phenotypes, bone mineral density (BMD), and osteoporosis risk. Numerous
genes have been related to the regulation of bone metabolism, and some of their polymorphisms have
been associated with variations in bone mass, osteoporosis predisposition, and fracture risk. However,
together these genetic variants account for less than 10% of the phenotypic variance in BMD [1].
Given the dynamic nature of bone functions, such as to be a major reservoir of essential
ions such as calcium and phosphate, this tissue has to provide very rapid responses to organic
changes and requirements, which are constantly granted by numerous and complex epigenetic
regulatory mechanisms of gene expression. Epigenetics consists of modular changes in gene and
protein expression that are independent of inherited DNA nucleotide sequences, and include histone
modifications, DNA methylation, and post-transcriptional microRNA (miRNA)-mediated negative
regulation of target mRNAs (Table 1 and Figure 1).
Epigenetic modifications are all reversible, highly dynamic, age-, cell-, and tissue-specific, and
sensitive to endogenous signals and/or environmental stimulation. Every individual may have
multiple epigenomes that can rapidly change during development, lifetime, and aging, in response
to internal and external signals, both in physiology and physiopathology. Epigenetic processes are
currently considered key mechanisms by which environmental factors and stochastic endogenous and
exogenous stresses may promote the development of numerous complex multifactorial pathologies,
such as osteoporosis. Moreover, recently, modification of epigenetic mechanisms and their activity has
also been associated with ageing. In this light, epigenetics could represent a link between the genome
and the environment, strongly influencing bone phenotypes and osteoporosis risk, together (and also
synergically) with inherited genetic variants, which could explain why genetic factors alone are not
sufficient to explain the predisposition to osteoporosis development and fracture occurrence (Figure 2).
Alterations in one or more epigenetic mechanisms can be associated with deregulation of bone
homeostasis, as described in detail in the next sections, and subsequent changes of bone-related gene
expression may help to account for the “missing heritability” of osteoporosis risk. Moreover, the
study and knowledge of these mechanisms, in normal or pathological bone tissues, may help both in
assessing osteoporosis and fracture risk and in driving therapeutic options, as well as in identifying
novel therapeutic anti-fracture molecules. Establishing the epigenetic signature in an individual could
help in tailoring appropriate treatments, according to the science of precision medicine.
Herein, the main epigenetic mechanisms involved in skeletal physiology and pathophysiology
will be described.
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Table 1. Main epigenetic mechanisms and their principal effects on gene expression.
Epigenetic Process
(Post-Translational
Histone Modifications)
Molecular Mechanism Involved Enzymes Mechanism of Action Effects on Gene Expression
Histone acetylation/
deacetylation
The lysine residues at the N-terminal
of histone tails are subjected to either
addition (acetylation) or removal
(deacetylation) of acetyl groups.
(1) Histone acetyltransferases
(HATs);
Acetylation removes positive charges from
lysine residues and reduces the affinity
between histones and DNA, thereby opening
the condensed chromatin structure, favouring
the access to gene promoters.
Histone acetylation promotes gene
expression. Conversely, histone
deacetylation prevents gene expression.(2) Histone deacetylases
(HDACs)
Histone methylation/
demethylation
Histone methylation occurs on
different lysine residues, with the
potential addition of one, two,
or three methyl groups.
(1) Histone lysine
methyltransferases (KMTs); The effect of histone methylation on chromatin
state is dependent not only on the specific
lysine residue modified, but also on its degree
of methylation.
Histone methylation at H3K4, H3K36,
or H3K79 has been associated with gene
transcription activation.
(2) Histone lysine demethylases
(KDMs)
Histone methylation at H3K9, H3K20,
or H4K27 is implicated in gene
expression inactivation or silencing.
DNA methylation
Addition of a methyl group at the 5′
position of the cytosine ring within
CpG islands of gene promoters.
(1) DNA methyltransferases
(DNMT3A and DNMT3B); Methylated gene promoters are not accessible
to transcription factors.
DNA methylation is strongly associated
with gene transcription silencing.(2) DNA maintenance
methyltransferase (DNMT1)
MicroRNAs (miRNAs)
miRNAs selectively bind to the 3’ non
coding region (3’UTR) of specific
target mRNAs, through base-pairing.
None
Binding of a miRNA on the 3’UTR of the target
mRNA blocks protein synthesis by two distinct
post-transcriptional mechanisms: mRNA
cleavage or translational repression.
miRNAs negatively regulate the
expression of target genes, at
post-transcriptional level, by blocking the
translation of their proteins.
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Figure 1. Schematic representation of the mechanism of action of epigenetic mechanisms. Histone 
acetylation positively regulates gene expression by inducing the opening of chromatin conformation 
and, thus, favouring the binding of transcription machinery. Histone methylation promotes the 
opening (panel A) or closing (panel B) of the chromatin conformation depending not only on the 
specific lysine residue modified, but also on its degree of methylation (Table 1). In this way, histone 
methylation can specifically induce or repress gene expression. MicroRNAs (miRNAs) suppress 
gene expression by selectively binding to the 3′ non coding region (3′UTR) of their mRNA  
targets through base-pairing. miRNAs can negatively regulate gene expression by two different 
post-transcriptional mechanisms: the cleavage of the mRNA target or the physical blocking of 
translation machinery. The choice of mechanism of action is determined only by the nucleotide 
complementarity between the miRNA and its mRNA target: the miRNA will cleave the target when 
it has sufficient complementarity to the miRNA itself, or it will repress translation, by physically 
blocking ribosome activity, if the mRNA does not have sufficient complementarity. In the first case, 
after the cleavage the miRNA remains intact and active and can proceed to the cleavage of other 
mRNA targets. 
Figure 1. Schematic representation of the mechanism of action of epigenetic mechanisms. Histone
acetylation positively regulates gene expression by inducing the opening of chromatin conformation
and, thus, favouring the binding of transcription machinery. Histone methylation promotes the opening
(panel A) or closing (panel B) of the chromatin conformation depending not only on the specific lysine
residue modified, but also on its degree of methylation (Table 1). In this way, histone methylation can
specifically induce or repress gene expression. MicroRNAs (miRNAs) suppress gene expression by
selectively bindin to the 3′ non coding region (3′UTR) of their mRNA targets through bas -pairing.
miRNAs can negatively regulate gene expression by two different post-transcriptional mechanisms:
the cleavage of the mRNA target or the physical blocking of translation machinery. The choice of
mechanism of action is determined only by the nucleotide complementarity between the miRNA and
its mRNA target: the miRNA will cleave the target when it has sufficient complementarity to the
miRNA itself, or it will repress translation, by physically blocking ribosome activity, if the mRNA does
not have sufficient complementarity. In the first case, after the cleavage the miRNA remains intact and
active and can proceed to the cleavage of other mRNA targets.
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Figure 2. Schematic representation of the role of genetics and epigenetics in bone development and 
maintenance. Static genetic traits and dynamic epigenetic marks interact with inner and outer 
environmental stimuli to determine bone features at all ages. While genetics may modulate the 
expression of epigenetics marks, epigenetic markers can regulate the expression of many genes 
coding for key molecules driving skeletal modelling in growing bone and remodelling in adult 
bone. Thus, all processes from bone development to peak bone mass attainment and maintenance 
can be influenced by epigenetic signatures, implying the possibility of modulating epigenetics in 
order to prevent/treat bone deterioration. 
Alterations in one or more epigenetic mechanisms can be associated with deregulation of bone 
homeostasis, as described in detail in the next sections, and subsequent changes of bone-related 
gene expression may help to account for the “missing heritability” of osteoporosis risk. Moreover, 
the study and knowledge of these mechanisms, in normal or pathological bone tissues, may help 
both in assessing osteoporosis and fracture risk and in driving therapeutic options, as well as in 
identifying novel therapeutic anti-fracture molecules. Establishing the epigenetic signature in an 
individual could help in tailoring appropriate treatments, according to the science of precision 
medicine. 
Herein, the main epigenetic mechanisms involved in skeletal physiology and pathophysiology 
will be described. 
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2. Post-Translational Histone Modifications in Bone Biology
Post-translational histone modifications include a large number of histone changes, such
as methylation, acetylation, phosphorylation, ubiquitination, ADP ribosylation, sumoylation,
deamination, and non-covalent proline isomerisation [2]. These modifications, induced or removed
by specific enzymes, alter the structure of chromatin, exposing or hiding gene promoters and, thus,
respectively, promote or repress gene transcription, through a dynamic phenomenon called the “histone
code”. One of the principal histone modifications is the acetylation/deacetylation process that adds or
removes acetyl groups to histone lysine side chains. Histone acetylation usually relaxes the chromatin,
allows transcription factors and RNA polymerase II to access the DNA, and, thus, is associated with the
promotion of gene transcription, while histone deacetylation induces compaction of the chromatin and
is responsible for blocking gene expression. Histone acetyltransferases (HATs) and histone deacetylases
(HDACs) act in a counteractive manner to regulate histone acetylation status in response to incoming
signals, and are involved in the control of numerous important biological processes (Figure 3).
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Figure 3. Schematic representation of the role of histone acetyltransferases (HATs) and histone 
deacetylases (HDACs). HATs induce histone acetylation by transferring an acetyl group from the 
acetyl coenzyme A to histone lysine side chains (mostly at histone 3 lysine 4 (H3K4Ac) or histone 3 
lysine 9 (H3K9Ac)), inducing the opening of chromatin status and promoting gene transcription. 
Conversely, HDACs remove the acetyl groups from histones, inducing the closing of chromatin 
status and blocking gene transcription. Histone deacetylase inhibitors (HDIs) inhibit the catalytic 
activity of HDACs by directly binding to their catalytic sites. 
Bone remodelling has also been demonstrated to be sensitive, at various cellular levels, to 
histone modifications. It is conceivable that these enzymes could rapidly regulate bone turnover in 
response to endogenous or external changes. Eighteen HDAC enzymes have been identified in 
humans, and several of them have been demonstrated to strongly contribute to regulate the correct 
skeletal development and accrual, bone mass peak acquisition, and optimal bone mass maintenance 
during lifetime and aging. These enzymes regulate histone acetylation status and directly 
deacetylate (i.e., inactivate) key proteins that drive bone homeostasis, such as the early osteoblast 
differentiation regulator Runt-related transcription factor 2 (RUNX2) (Table 2). HDACs are divided 
into four classes (I, II, III, and IV) based on their structure, function, cellular localization, and 
expression. Classes I, II, and IV (commonly referred as HDACs) present a zinc-dependent catalytic 
sites, while class III (commonly named as Sirtuins; Sirts) needs NAD+ for the catalytic action. 
HDAC1 and HDAC2 are highly homologous and can form hetero- or homo-dimers with each 
other. They both play a role in suppressing osteoblastogenesis, and levels of their mRNAs are 
usually decreased during osteoblast differentiation to grant the correct development of this  
process [3]. Recently, it has been shown that HDAC2 expression is increased during receptor 
activator of nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation of bone 
marrow-derived precursors [4]. It was revealed to be a key regulator of osteoclastogenesis by 
Figure 3. Schematic representation of the role of histone acetyltransferases (HATs) and histone
deacetylases ( s). Ts induce histone acetylation by transferring an acetyl group from the acetyl
coenzyme A to histone lysine side chains (mostly at histone 3 lysine 4 (H3K4Ac) or histone 3 lysine 9
(H3K9Ac)), inducing the opening f chromatin status a d promoting gene tra scription. Conversely,
HDACs remove the acetyl groups from histones, inducing the closi g of chromatin status and blocking
gene transcriptio . Histone deacetylase inhibitors (HDIs) inhibit the catalytic activity of HDACs by
directly binding to their catalytic sites.
Bone re odelling has also been demonstrated to be sensitive, at various cellular levels, to histone
modifications. It is conceivable that these enzymes could rapidly regulate bone turnover in response to
endogenous or external changes. Eighteen HDAC enzymes have been identified in humans, and several
of them have been demonstrated to strongly contribute to regulate the correct skeletal development
and accrual, bone mass peak acquisition, and optimal bone mass maintenance during lifetime and
aging. These enzymes regulate histone acetylation status and directly deacetylate (i.e., inactivate) key
proteins that drive bone homeostasis, such as the early osteoblast differentiation regulator Runt-related
transcription factor 2 (RUNX2) (Table 2). HDACs are divided into four classes (I, II, III, and IV) based
on their structure, function, cellular localization, and expression. Classes I, II, and IV (commonly
referred as HDACs) present a zinc-dependent catalytic sites, while class III (commonly named as
Sirtuins; Sirts) needs NAD+ for the catalytic action.
DAC1 and DAC2 are highly ho ologous and can for hetero- or ho o-di ers ith each
other. They both play a role in suppressing osteoblastogenesis, and levels of their R As are
usually decreased during osteoblast differentiation to grant the correct development of this process [3].
Recently, it has been shown that HDAC2 expression is increased during receptor activator of nuclear
factor-κB ligand (RANKL)-induced osteoclast differentiation of bone marrow-derived precursors [4].
It was revealed to be a key regulator of osteoclastogenesis by activating Akt kinase that directly
phosphorylates and inhibits Forkhead box protein O1 (FoxO1), a negative regulator of osteoclast
differentiation [4].
HDAC3 is highly expressed in osteoblasts at all stages of differentiation, and it directly interacts
with the transcription factor RUNX2 [5]. This enzyme was demonstrated to be important for bone mass
acquisition and maintenance during aging, and for correct craniofacial development. Mouse models
deficient in HDAC3, in osteochondral precursor cells, showed reduced bone length and decreased
cortical and trabecular bone mass and mineralization, severe osteoporosis, and suffered frequent
fragility fractures [6]. The complete germline knockout of HDAC3 is lethal at the embryonic level [7].
Conversely, the RNA interference-driven in vitro suppression of HDAC3 in pre-osteoblasts increases
matrix mineralization [5].
HDAC4 has been shown to directly deacetylase RUNX2, repressing its transcriptional activity
and promoting its degradation in mature osteoblasts [8]. Loss of HDAC4 in mouse models accelerates
endochondral bone formation, inducing premature ossification of multiple cartilaginous sites that
Int. J. Mol. Sci. 2016, 17, 1329 7 of 19
lead to severe skeletal defects, including shortened long bones, vertebral body fusion, and premature
endochondral ossification of the skull. Conversely, the over-expression of Hdca4 results in a severe
deficit of endochondral ossification and slows the ossification of cartilage in vivo [9]. Intramembranous
bone formation is normal in both cases, proving that HDAC4 has a role specifically in regulating
the process of endochondral ossification from cartilage. HDAC4 also directly controls bone
morphogenetic protein (BMPs) and TGFβ signalling during bone development [10]. In humans,
loss-of-function mutations of the HDAC4 gene were found to be the cause of Brachydactyly-Mental
Retardation syndrome, characterised by distinctive craniofacial features and shortened metacarpal
and metatarsal bones.
Conversely, HDAC8 has a crucial role in intramembranous ossification. Indeed, germline deletion
of this gene in mice is detrimental to skull bone formation and leads to perinatal death [11]. In humans,
inactivating mutations of the HDAC8 gene has been identified in patients with Cornelia de Lange
syndrome and with a clinical condition similar to Wilson-Turner linked mental retardation syndrome,
both characterized by shortened long bones and distinctive craniofacial dimorphisms [12,13],
the former also by delayed fontanel closure and small hands and feet.
HDAC5 is expressed in mature osteoblasts where, in association with HDAC4 and TGFβ1,
it represses the transcriptional activity of RUNX2 [8], and also directly deacetylates RUNX2, promoting
its Smurf-mediated degradation. Two related young patients with primary juvenile osteoporosis
showed elevated HDAC5 protein level and reduced RUNX2 expression in bone [14].
HDAC7 is highly expressed both in mature osteoblasts and in osteoblast precursors, and it
has been demonstrated to repress RUNX2 by deacetylation-independent mechanisms [15] and to
be necessary for endochondral ossification. In vitro suppression of HDAC7 by RNA interference
favours osteoblast differentiation in a bone morphogenetic protein 2 (BMP2)-dependent manner [15].
Inactivation or suppression of HDAC7 expression results in proliferation of osteoclast precursors
and promotion of RANKL-induced osteoclastogenesis [16]. Also, HDAC9 knock-out mice showed an
increased number of active osteoclasts, a higher bone resorption, reduced bone formation indices, and
an osteopenic phenotype. Conversely HDAC9 expression suppresses osteoclastogenesis, presumably
by negatively regulating Rankl expression. These data suggest a possible involvement of HDAC7 and
HDAC9 in osteoporosis [17].
Sirt1 and Sirt6 are the only class III HDACs that have shown, to date, a proven role in bone
tissue development and metabolism [17]. Activation of Sirt1 in mesenchymal stem cells (MSCs)
promotes osteogenic differentiation, blocking adipocyte differentiation. Conversely, inhibition of Sirt1
expression results in a promotion of adipogenic differentiation [18]. Ovariectomy and subsequent
estrogen depletion result in Sirt1 protein absence in animal models; this could explain the increased
adiposity in bone marrow and the rapid bone loss after menopause. The restoration of Sirt1 expression
could reveal a possible approach to preventing post-menopausal osteoporosis. Both Sirt1 and Sirt6
facilitate endochondral ossification—Sirt6, particularly, by controlling chondrocyte proliferation
and differentiation.
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Table 2. Role of histone deacetylases (HDACs) in bone biology.
HDAC Class Affected Protein Expression Effects on Bone Biology Reference
HDAC1 I RUNX2 (down-regulation) Suppression of osteoblast differentiation [6]
HDAC2 I FoxO1 (down-regulation) Promotion of RANKL-induced osteoclastogenesis [13]
HDAC3 I RUNX2 (down-regulation) Maintenance of bone mass during developmentand aging [3]
HDAC4 II RUNX2 (down-regulation) Suppression of endochondral ossification [8,9]
HDAC5 II RUNX2 (down-regulation) Suppression of osteoblast differentiation [8]
HDAC7 II RUNX2 (down-regulation) Regulation of endochondral ossification [15]
HDAC8 I
Homeobox transcription factors
Otx2 (up-regulation) and Lhx1
(up-regulation)
Regulation of intramembranous ossification [11]
HDAC9 II RANKL (down-regulation) Suppression of osteoclastogenesis [17]
Sirt1 III NA Promotion of endochondral ossification, and ofosteoblast differentiation of mesenchymal stem cells [17,18]
Sirt6 III NA Promotion of endochondral ossification [17]
NA = non available.
Histone deacetylase inhibitors (HDIs, i.e., valproic acid, trichostatin A) are small molecules
able to inactivate HDACs (Figure 3) by binding to their zinc-containing catalytic sites. HDIs have
been demonstrated to induce a transient increase in osteoblast proliferation and viability, to enhance
osteoblast differentiation in vitro, to augment alkaline phosphatase (ALP) production and expression of
type I collagen, osteopontin (OPN), bone sialoprotein, osteocalcin (OCN), and RUNX2, and to accelerate
the extracellular mineralization in osteogenic cell lines and mesenchymal progenitor cells [19].
Moreover, these molecules induce MSCs to differentiate into mature osteoblasts. HDIs have also been
demonstrated to block the formation of pre-osteoclast-like cells and their fusion into multinucleated
osteoclast-like cells in rat bone marrow cell culture, and to reduce osteoclast-specific synthesis of
cathepsin K [20], and to act on mature osteoclasts, causing their apoptosis [21]. The increased
acetylation of histones H3 and H4, at the RANKL promoter, favours RANKL transcription, indicating
that epigenetic chromatin remodelling is involved in RANKL expression [22] and, thus, in the
regulation of osteoclast activation.
These in vitro results suggest a possible application of HDIs as anti-fracture therapy in
osteoporosis, able both to reduce osteoclast bone resorption and promote osteoblast bone formation.
However, both in vivo studies in animal models [23,24] and human epidemiological studies on HDI
treatment for epilepsy and mental disorders [25,26] evidenced a negative effect of prolonged HDI
therapy on BMD value, associated, in some cases, with a higher risk of fracture [27]. The molecular
causes of controversial results between HDI effects on bone in vitro or in vivo, as well as the exact
mechanisms by which HDIs reduce BMD in vivo, remain to be fully elucidated. Current HDIs
act on various different HDACs, which play crucial roles at various points of osteoblastogenesis,
so that long-term HDI therapy can affect all of them at the same time. Ideal HDIs should target
only one specific HDAC. With this in mind, a new generation of drugs of this kind is currently
under development.
Recently, a study by Feng et al. tested the ability of resveratrol, a plant polyphenol acting as
an agonist of Sirt1, to promote osteogenesis in vitro and prevent bone loss in animal models and,
thus, its possible protective effect on osteoporosis [28]. In rats with bilateral ovariectomy, resveratrol
moderately restored the serum level of ALP and OCN and improved bone structure. Moreover,
resveratrol promoted the in vitro osteoblast differentiation of bone marrow mesenchymal stromal cells
via the Sirt1-NF-κB signalling pathway. The authors demonstrated that the beneficial bone effects of
resveratrol were exerted by its direct action on Sirt1, since the RNA silencing of Sirt1 resulted in a loss
of any positive effect of resveratrol administration. These results suggested a therapeutic potential of
resveratrol against post-menopausal osteoporosis.
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Histone methylation is another common histone modification, finely tuned by the opposing
enzymatic actions of histone lysine methyltransferases (KMTs) and histone lysine demethylases
(KDMs). The histone methylation state has been revealed to be an important modulator of MSC
differentiation into the osteogenic lineage or the adipogenic lineage. SETDB1 and EZH2 are two KMTs
that inhibit osteogenic differentiation of MSCs via blocking RUNX2, transcription factor 7 (TCF7),
and Osterix (OSX) transcription, and promote adipogenesis of MSCs by inducing the expression of
peroxisome proliferator-activated receptors gamma (PPARγ), myocyte enhancer factor 2 interacting
transcriptional repressor (MITR), and Wnt-related genes [29]. Conversely, KDM4B, KDM6A, and
KDM6B are KMTs that promote osteogenesis and repress adipogenesis by inducing the transcription
of RUNX2, BMP, OCN, distal-less homeobox 5 (DLX5), and HOX-related genes [29]. Other numerous
KMTs are involved in the alternative regulation of these two differentiation processes and, thus, in normal
bone turn-over or pathologies, and they have been extensively reviewed elsewhere recently [29].
3. DNA Methylation in Bone Biology
DNA methylation consists of the reversible covalent addition of a methyl group to the fifth
carbon of a cytosine residue (5-mC) located in the CpG islands of gene promoters, and it is
commonly associated with the repression of gene expression. The enzymes responsible for DNA
methylation are de novo DNA methyltransferases (DNMT3A and DNMT3B) that act preferentially
on unmethylated and hemimethylated DNA and are important during embryo development, and
maintenance methyltransferase (DNMT1) with a preference for hemimethylated DNA and able to
maintain the methylation patterns during DNA replication. Demethylation is both a passive reduction
of methylation during DNA duplication and an active mechanism not yet fully elucidated.
DNA methylation state has an important role in both bone metabolism and age-related disorders,
such as osteoporosis. Methylation of several genes is involved in the regulation of bone cell
differentiation and in the normal bone remodelling process. In osteoblasts, DNA methylation state
co-regulates the expression of various important genes involved in bone cell functions, such as
alkaline phosphatase (ALPL), sclerostin (SOST), OSX, DLX5, oestrogen receptor alpha (ESR1), OPN,
RANKL, osteoprotegerin (OPG), secreted frizzled-related protein 1 (SFRP1), and leptin (LEP) [30].
ALPL promoter methylation is inversely associated with gene transcription and expression and
is differently regulated at different stages of osteoblast differentiation. Indeed, osteoblasts show
poor ALPL methylation, bone lining cells have an intermediate methylation status, and an ALPL
hypermethylation is characteristic of osteocytes, associated with no expression of ALPL gene.
In parallel, transition from osteoblasts to inactive osteocytes is associated with a progressive reduction
in levels of SOST promoter methylation.
Little is known about DNA methylation and the regulation of osteoclast differentiation and activity.
It can be also inferred that DNA methylation has a direct role in the pathogenesis of osteoporosis, but,
to date, few studies directly support this hypothesis, and results are still inconclusive.
Recently, a study by Nishikawa et al. [31] demonstrated that Dnmt3a positively regulates
osteoclast differentiation by methylation, and expression induction, of the S-adenosylmethionine
(SAM) gene. SAM protein expression results in the induction of osteoclastogenesis by repression
of anti-osteoclastic genes, such as RANKL. The authors also showed that mice osteoclast precursors
deficient in Dnmt3a were unable to efficiently differentiate into mature osteoclasts in vitro, and that
Dmnt3a knock-out mice model showed a reduced number of active osteoclasts and a higher bone
mass with respect to the normal control. Furthermore, they investigated the possibility that targeted
Dnmt3a inhibition may have a positive effect in preventing bone loss, by administration of the Dnmt3a
inhibitor theaflavin-3,3′-digallate (TF-3) to ovariectomized female mice, as a model of postmenopausal
osteoporosis. Treatment with TF-3 resulted in a reduction of number of activated osteoclasts, a higher
bone mass, and protection against bone loss, suggesting that the inhibition of Dnmt3a could be a
beneficial strategy for preventing bone loss and controlling postmenopausal osteoporosis. Human
clinical trials on osteoporosis and other bone disorders characterized by excessive osteoclast activity are
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surely needed to confirm this preliminary result and to design a possible novel therapeutic approach
for these diseases.
Analysis of DNA methylation in bone tissue samples from osteoporotic subjects, with respect to
control individuals, revealed a hypermethylation of OPG and RANKL CpG islands, which influences
the transcription level of these genes and, subsequently, the osteoclastogenesis [32]. However,
the concomitant increase of the RANKL: OPG ratio in patients with osteoporotic fractures seemed to
be derived from other methylation-independent mechanisms [32].
A case-control study analysed DNA methylation at four regions upstream of the SOST
transcription start site in bone biopsies from post-menopausal osteoporotic women and normal
BMD controls, indicating a statistical difference in methylation state between affected patients and
the healthy group [33]. The authors suggested that the increased methylation of SOST promoter in
osteoporosis could be a mechanism that, through the reduction of serum SOST protein level and,
subsequently, the enhancement of canonical Wnt signalling, aims to induce compensatory bone
formation, counteracting osteoporosis-associated bone loss.
A genome-wide study evaluated the DNA methylation profile, at the genome level (methylation
of 23,367 GpG sites in 13,463 genes was analysed), in femoral head trabecular bone specimens
from osteoporotic hip fractures with respect to hip samples of patients with osteoarthritis [34].
The results showed an inverse correlation between methylation and whole gene expression in both
cases. A significant difference in methylation level was found in 241 CpG sites located in 228 genes,
the great majority of them involved in glycoprotein, neuronal differentiation, adherence, homeobox,
and cell proliferation pathways. Among these, the homeobox superfamily genes, differentially
methylated between osteoporosis and osteoarthritis, include genes that are directly involved in
skeletal embryogenesis. It could be hypothesised that the existence of one or more developmental
regulatory components, probably including DNA methylation, acting during development and growth,
is responsible for correct skeletal formation and homeostasis and also for the further development of
osteoporosis or osteoarthritis during aging.
Environmental factors have been associated with DNA methylation and skeletal development
during the early phase of embryogenesis in animal studies and in humans. Indeed, maternal dietary
habits influence the bone mass of the progeny [35,36], presumably also through the induction of
methylation variations and/or changes in histone modifications in genes important for bone cell
differentiation and function, such as PPARγ and glucocorticoid genes [37,38].
DNA methylation patterns are highly cell-specific, and can differ between different stages during
a lifetime or in correlation with diseases. Therefore, they could be used as viable diagnostic, prognostic,
and/or therapy-guiding biomarkers in numerous biological samples, thanks also to the great stability
of methylation in spite of external perturbations and sample manipulations. In this light, large-scale
studies comparing methylation states between cases and relative controls can identify this epigenetic
trait associated with specific disorders. Nevertheless, unlike in tumours, where DNA methylation
screenings have validated clinical applications, no methylation tests are currently available or under
investigation for common bone disorders.
4. miRNAs in Bone Biology
miRNAs are endogenous single-stranded small non-coding RNAs that negatively regulate gene
expression, at the post-transcriptional level, by selectively binding to the 3′ non-coding region (3′UTR)
of specific target mRNAs through base pairing. By this mechanism, miRNAs can suppress the
expression of their target proteins by directly blocking the translation process or enhancing the
degradation of mRNAs. Over 2000 human miRNAs have been identified, to date, all of them
involved in the regulation of important biological processes such as development, cell growth, and
cell differentiation. The fundamental role of miRNAs in the regulation of growth and differentiation
of both osteoclasts and osteoblasts has been clearly assessed. Indeed, the genetic deletion of Dicer,
the enzyme responsible for maturation and activation of all miRNAs, in osteoblast progenitors [39] and
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pre-osteoclast lineage cells [40] resulted, respectively, in severe impairment of osteoblast differentiation
and maturation with subsequent alterations in bone tissue structure and matrix mineralization, or in a
reduced number of active osteoclasts with subsequent decreased bone resorption and osteopetrosis.
Dicer excision in differentiated osteoblasts results in an increased bone mass in adult mice, with double
cortical bone width and trabecular thickness with respect to normal controls [39].
In recent years, numerous miRNAs have been demonstrated to directly regulate, either positively
or negatively, osteoblastogenesis and osteoclastogenesis, by interacting with specific factors involved
in the control of these two processes. Herein, a brief overview of the principal miRNAs involved in
the regulation of osteoblast or osteoclast differentiation is given, with the description of their specific
action in these processes.
Fourteen miRNAs (miR-23a, miR-30a-d, miR-34c, miR-133a, miR-135a, miR-137, miR-204,
miR-205, miR-211, miR-217, miR-218, miR-335, miR-338, miR-433, and miR-3077-5p) target the 3′UTR
of RUNX2, the master transcription factor in osteoblast differentiation [41–44]. All these miRNAs
control osteogenic differentiation at different levels, blocking the osteoblast lineage progression of
committed pre-osteoblasts or directing multi-potent mesenchymal stem cells toward adipogenic
differentiation. Conversely, two miRNAs, miR-2861 and miR-3960, have been shown to indirectly
induce RUNX2 expression by targeting its inhibitors HDAC5 and HOXA2, and, thus, promoting
osteoblast differentiation [45]. miR-2861 and miR-3960 are transcribed together from the same miRNA
polycistron during BMP2-induced osteogenesis. Over-xpression of miR-2861 and miR-3960 promotes
BMP2-induced osteoblastogenesis, while their inhibition reduces osteoblastogenesis. RUNX2 itself was
demonstrated to directly bind to the promoter of miR-3960 and miR-2861, positively regulating their
expression. Moreover, it has been shown that RUNX2 negatively regulates the expression of the miR
cluster 23a-27a-24-2, by DNA direct binding to specific elements in the promoter of these genes [46].
The reduced expression of this miR cluster is responsible for the promotion of osteoblast differentiation.
Taken together, all these data suggest that the RUNX2 factor establishes complex regulatory networks
with miRNAs that play, in this way, a central role in the control of correct progression and maintenance
of the osteoblast phenotype.
A homozygote mutation of the gene encoding miR-2861 has been associated with a rare form
of primary juvenile osteoporosis in two adolescents [14]. Consistent with data obtained from mouse
models, bone samples from these two patients showed increased levels of HDAC5 and decreased
levels of RUNX2, confirming that miR-2861 is an important physiological regulator of osteoblast
differentiation. Thus, deregulation of miR-2861 can contribute to the establishment of osteoporosis via
its effect on osteoblasts and could be an optimal target for future anti-osteoporotic therapies.
Also, BMPs and the Wnt signalling pathway, fundamental and key mechanisms driving
skeletal-related gene expression involved in the formation of cartilage and bone, have been
demonstrated to interact with various miRNAs to control osteoblast differentiation.
BMP2 controls the switch between muscle and bone differentiation by regulating miRNA
expression. BMP2 has been shown to downregulate 22 miRNAs that inhibit the translation of crucial
factors of osteoblastogenesis, by directly targeting their 3′UTR, such as SMAD5 (the intracellular
receptor of BMP2 within pre-osteoblasts) and RUNX2 [42]. Indeed, two miRNAs downregulated by
BMP2, miR-135 and miR-133, are, respectively, negative regulators of SMAD5 and RUNX2. miR-135
inhibits directly SMAD5 expression, and, thus, indirectly also RUNX2 expression. miR-133 showed the
dual function of promoting myogenesis and, at the same time, inhibiting differentiation of MSCs into
the osteoblast lineage.
Specific miRNAs were shown to regulate the Wnt/β-catenin signalling pathway, interfering with
osteoblast differentiation. miR-29a gene expression is enhanced by canonical Wnt signalling, and its
expression is increased during osteogenic differentiation of mesenchymal osteoblast precursors [47].
miR-29a targets and inhibits expression of Dikkopf-1 (DKK1), Kremen2, and secreted frizzled related
protein 2 (SFRP2), three key negative regulators of Wnt signalling, thus potentiating the effect of Wnt
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signalling, promoting the expression of Wnt-regulated genes, and favouring osteoblast differentiation
and bone formation.
Wnt signalling also induces the expression of miR-128 during osteoblast differentiation,
while miR-128 promotes osteogenic commitment and differentiation of bone marrow MSCs by directly
inhibiting the translation of three repressors of Wnt signalling, SOST, Dickkopf-2 (DKK2), and SFRP2,
through a positive feedback loop [48].
Additional miRNAs enhance osteoblast differentiation through the modulation of the canonical
Wnt pathway. miR-335-5p activates Wnt signalling and promotes osteogenic differentiation by
downregulating DKK1, and is highly expressed in both osteoblasts and hypertrophic chondrocytes
during embryogenesis [49]. Treatment of pre-osteoblasts with anti-miR-335-5p reverses the effect of
miR-335-5p and reduces osteoblastogenesis. miR-27 is overexpressed during osteoblast differentiation,
and its inhibition is associated with blocking of cell differentiation [50]. miR-27 directly targets and
inhibits adenomatous polyposis coli (APC) gene expression, a fundamental component of the axin
complex that positively regulates phosphorylation and subsequent degradation of β-catenin, by blocking
the Wnt signalling. Inactivation of APC by miR-27 induces the accumulation of β-catenin, its translocation
into the nucleus, and the transcription of Wnt-regulated genes, resulting in a promotion of osteogenesis.
Increased expression of miR-142-3p has been seen during osteoblast differentiation of mesenchymal
precursors [51]. This miRNA acts in the same way as miR-27, by targeting and repressing APC.
All miRNAs described above are important positive or negative mediators of osteoblast
differentiation (Figure 4), and could be novel promising targets for the development of preventive or
therapeutic agents against osteogenic disorders.
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Three principal miRNAs have been associated with the regulation of osteoclastogenesis: miR-21,
miR-155, and miR-223. A significant stimulation of miR-21 during RANKL-induced osteoclastogenesis
has been found [52]. miR-21 targets programmed cell death 4 (PDCD4). The PDCD4 protein is known
to directly negatively affect the activity of the transcription factor AP1. This results in decreased
expression of AP1-regulated genes such as c-FOS, an important transcription factor for inducing
osteoclast differentiation and osteoclast-specific downstream target genes. Diminished expression
of PDCD4, by miR-21, remov s the repression from c-FOS expression and promot osteoclast
differ ntiation. Moreover, it has been shown that RANKL-induc s c-FOS expression that upregulates
miR-21 expression in a positive feedback loop responsible for promotion of RANKL-mediated
osteoclastogenesis. The high expression of miR-21 promoting osteoclast differentiation is inhibited by
oestrogens [53]. In particular, oestrogens downregulate miR-21 biogenesis, resulting in an increase
of Fas Ligand (FasL, a target of miR-21), which induces the apoptosis of osteoclasts [53]. These data
could suggest miR-21 as a target for novel antagomir-based antiresorptive therapy as an alternative to
oestrogen replacement therapy in post-menopausal women.
Conversely, miR-155 has a suppressive effect on osteoclast differentiation in vitro, mediated by its
inhibition of expression of SOCS1 and MITF, two essential pos tive regulators of osteoclastog n sis [54].
Expression of miR-155 is induced by interferon-β, which, in this way, exerts n gative action
on osteoclast differentiation. miR-155 could represent a novel viable agent for the treatment of
osteoclast-mediated diseases, such as osteoporosis, but its systemic role in osteoclast suppression and
bone remodelling remains to be clearly elucidated.
Another miRNA, miR-223, plays a critical role in osteoclast differentiation. An increased
expression of miR-223 blocks the maturation of pre-osteoclastic cells into tartrate-resistant acid
phosphatase (TRAP)-positive multinucleated mature osteoclasts, while normal expression of
miR-223 f vours this c ll differentiation [55]. A recent study associated low expr ssion of miR-223
with th promotion of osteoclastogenesis [56]. High c ncentrations of inorganic phosphate (Pi)
decreased miR-223 expression in osteoclast precursors in vitr , resulting in a marked decre se in
osteoclastogenesis. miR-223 targets the Nuclear Factor IA (NFIA), a negative regulator of macrophage
colony stimulating factor (M-CSF), and Ras homolog gene family ()member B RhoB, a transcription
factor involved in cell proliferation. Data from these two studies suggested that both too high or too
low a level of miR-223 precludes efficient osteoclast differentiation, and indicated that this miRNA is a
promising therapeutic target for bone metabolic disorders characterised by excessive osteoclast activity.
Given their important roles in the normal regulation of osteoblast and osteoclast development
and function, deregulation of miRNA activity is surely an important factor in bone disorders.
Three mechanisms could be responsible for altered functions of specific miRNAs in bone tissue,
leading to the development of osteoporosis or other metabolic bone disorders: (1) mutations in genes
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encoding miRNAs involved in the regulation of bone metabolism, which deregulate their function
and/or their expression; (2) mutations affecting the 3’UTR binding sites of target mRNAs, fundamental for
the regulation of transcription, and modulated by miRNAs; (3) abnormalities in miRNA expression altering
regulatory networks involved in the control of osteoblast and/or osteoclast differentiation and activity.
Recently, it has been demonstrated that miRNAs are not only active locally within the cells that
express them, but can also be secreted via extracellular microvesicles or exosomes. Indeed, circulating
miRNAs have been identified in 12 different body fluids [57]. Circulating miRNA signatures have been
identified as diagnostic and/or prognostic biomarkers of various disorders, including age-associated
diseases. The role of circulating miRNAs as biomarkers for osteoporosis and other metabolic bone
disorders has not received much attention until recent years. Indeed, the finding that osteoblasts
seem to communicate via exosome shuttling and the discovery that exosome miRNA content changes
during osteoblast differentiation both support the possible use of extracellular miRNAs as biomarkers
of bone metabolism. Circulating miRNAs have the potential to be surrogate biomarkers (bioproducts)
of bone metabolism as well as provide information on the cellular and molecular processes involved
in bone turnover and be minimally invasive markers with specific functional relevance to osteoblast,
osteoclast, and osteocyte differentiation and activity. Measurement of specific serum miRNAs could
help in the near future to identify patients at high risk of osteoporosis and fragility fractures and/or
to monitor the efficacy of antiresorptive therapies and bone-forming agents, either used alone or in
association with existing biological markers of bone metabolism.
In this setting, few studies have tried to identify circulating miRNAs associated with BMD,
osteoporosis, and fracture risk. Li et al. evaluated, by quantitative RT-PCR (RT-qPCR), the expression
of three specific miRNAs (miR-21, miR-133a, and miR-146) in the plasma of 120 post-menopausal
Chinese women with normal, osteopenic, or osteoporotic range of BMD, evidencing a higher level
of miR-133a and a lower level of miR-21 in osteoporotic and osteopenic women with respect to the
normal group [58]. Seelinger et al. measured an 83-miRNA RT-qPCR panel in a pool of 10 serum
samples from osteoporotic Caucasian men and women vs. a pool from 10 non-osteoporotic Caucasian
women, both with hip fractures [59]. Results from PCR-array have been validated on further serum
samples from 30 osteoporotic patients vs. 30 normal controls and on miRNA samples isolated from
the bone tissue of 20 osteoporotic and 20 non-osteoporotic patients. A signature of nine circulating
miRNAs (miR-21, miR-23a, miR-24, miR-93, miR-100, miR-122a, miR-124a, miR-125b, and miR-148a)
has been found to be significantly upregulated in patients with osteoporosis, with miR-21, miR-23a,
miR-24, miR-25, miR-100, and miR-125b displaying significantly higher expression in bone tissue from
osteoporotic patients. Weilner et al. tested a panel of 175 miRNAs on serum samples from seven female
patients with recent osteoporotic hip fracture and seven age-matched female controls [60]. Six miRNAs
(miR-10a-5p, miR-10b-5p, miR-22-3p, miR-133b, miR-328-3p, and let-7g-5p) showed significantly
different serum levels in the presence of a fracture. These data were validated on a further 12 fractured
women vs. 11 controls, confirming miR-22-3p, miR-328-3p, and let-7g-5p as differentially expressed
in the presence of a fracture. Panach et al. measured a panel of 179 miRNAs in the serum samples
of eight osteoporotic women with fractures vs. five controls, and validated data on 15 patients with
fractures vs. 12 controls [61]. They determined that miR-122-5p, miR-125b-5p, and miR-21-5p were
upregulated in the presence of a fracture. In particular, for miR-21-5p, the difference detected between
fractured women and controls was independent of age, and its circulating levels were correlated to
those of CTx, a marker of bone resorption.
These studies support a future application of circulating miRNA dosage as a biomarker for
assessing osteoporosis status and fracture risk. However, all these studies analysed a small number
of samples, strongly reducing the efficacy of association, and they evaluated only restricted panels
of miRNAs. Further studies are surely needed, including larger populations and the application of
high-throughput technologies, such as next-generation sequencing (NGS), to evaluate, at the same
time, all the known human miRNAs, in order to identify specific signatures, possibly driving diagnosis
and therapeutic choices.
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5. Discussion
Epigenetics mechanisms play a fundamental role in regulating biological processes, also in
response to exogenous environmental influences. In this light, there is increasing epidemiological and
biological evidence that some environmental stimuli, such as viral and bacterial infections, prolonged
exposition to chemical agents and pollutants, an imbalance of nutrients, long-term pharmacological
treatments, and physical and mental stresses, can induce important epigenetic changes, significantly
influencing gene expression and biological processes. They can result in favouring and/or promoting
the development of complex multifactorial disease during aging. Since it is now well known that
epigenetic factors play a major role in skeletal development and bone maintenance, a deregulation
of these regulatory mechanisms, induced by environmental factors (i.e., dietary habits and lifestyle
aspects), could be an important determinant of the development of osteoarticular diseases, including
osteoporosis, acting in a synergic manner with predisposing genetic determinants. Indeed, bone
development at the embryo stage and skeletal growth and bone mass peak acquisition during
infancy, adolescence, and early adulthood, as well as bone mass maintenance during aging and
bone progressive loss in the elderly, can all be modified by environmental influences such as maternal
and perinatal nutrition, dietary habits, physical activity, smoke, alcohol intake, hormonal therapies, etc.
The effect of these exogenous factors on bone metabolism is mediated by the epigenetic mechanisms.
In particular, nutri-epigenetic studies demonstrated the influence of some nutrients on foetal and/or
placental epigenetic mechanisms. Food is more than simple energy for our body and/or the main
source of key metabolites for synthesis of biological macromolecules and cell and tissue activity.
Nutrients are important determinants of epigenetic functions and can exert variable effects on these
endogenous regulatory mechanisms; derived early epigenetic modifications can alter gene expression
in a way that may influence long-term health and diseases. Indeed, maternal nutritional imbalance and
deficiency not only have a severe effect on correct foetal development but may also have a persistent
effect on the health of the offspring and even be transmitted to the next generation [62]. Maternal
diet influences post-natal bone mass and size, and birth weight has been positively associated with
young adult bone mineral content and bone size [63,64] and with adult hip and spine bone mineral
content [65]. Low maternal calcium and vitamin D intake during late pregnancy has been associated
with reduced bone mineral content. Maternal under-nutrition or maternal high fat diet were both
demonstrated to affect DNA methylation of the foetus during intrauterine development, altering the
pre- and post-natal expression of multiple genes that may regulate skeletal growth and bone mass
acquisition. Prenatal and perinatal diet-induced DNA methylation changes can persist during life
and also for multiple generations. A review by Bocheva et al. [66] gives an interesting overview of the
epigenetic modulation of intrauterine and post-natal skeletal development and of placental transfer of
nutrients and their future impact on osteoporosis development.
In this light, a better comprehension of the effect of maternal diet on skeletal development and
bone mass determination and of the exact underlying epigenetic mechanisms is needed. This will be
very helpful to design and activate large-scale public health nutrition programs for pregnant women,
infants, and children, in order to reduce the risk of osteoporosis and fragility fracture in the elderly.
Regarding molecules influencing epigenetic mechanisms that could find a future application in
the area of treatment of metabolic bone disorders, currently few preliminary data are available on
resveratrol, HDIs, and TF-3. The effects of HDIs on bone tissue appear to be controversial and should be
better investigated in prospective clinical trials, focusing on the design of novel HDIs not targeting a wide
range of HDACs but specific for only one enzyme. Also, the beneficial effect of resveratrol on bone mass
and the protective effect of TF-3 on bone loss both need to be confirmed and validated in clinical trials.
Calcium is commonly administered as a supplement for the prevention and treatment of
osteoporosis. A recent study [67] showed that in the presence of a high concentration of calcium
ions and in the absence of reducing agents, vertebrate DNMTs (principally DNMT1, DNMT3B, and,
to a lesser extent, DNMT3A) can act, in vitro, as demethylases and remove the methyl group from
the 5-mC, altering the normal DNA methylation status and presumably having an effect on gene
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expression and the risk of associated disease development. No data are available on the effect of
this activity on bone cells, and since the calcium ion concentration (≥10 µm) needed for the in vitro
DNA demethylation reaction is higher with respect to the normal intracellular level of calcium, the
intervention of other cofactors and/or specific signal transduction pathways could be required for the
in vivo demethylation reaction to act.
6. Conclusions and Future Perspectives
In conclusion, better comprehension of both normal and deregulated epigenetic processes in bone
metabolism will provide insights into normal skeletal development and maintenance, as well as into
disease pathogenesis. Increasing advances in high-throughput technologies for epigenetic research,
as well as the progressive reduction of the cost-efficiency ratio will enable, in the near future, a better
understanding of the epigenetic basis of both normal and pathological bone metabolism, helping us to
develop better diagnostic tools, foresee disease development, grant a more favourable prognosis, and
identify novel drug target for the design of innovative therapies.
Moreover, since the epigenome—conversely to the genome—is reversible, we could manipulate
identified altered epigenetic processes responsible for the development of diseases. Indeed, epigenetic
mechanisms can be specifically targeted by pharmacological agents, an approach that was
demonstrated to be effective in some tumours and neurological disorders and that also holds great
promise for future treatment of bone diseases. In the setting of precision medicine, all these features
can be exploited to grant tailored treatment for the individual.
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